Related Experiment Video
Updated: Jun 19, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[HCV entry as a new therapeutic target in chronic hepatitis C]
Magdalena M Dabrowska1, Anatol Panasiuk, Robert Flisiak
1Medical University of Białystok, Department of Infectious Diseases and Hepathology, Poland. m.dabrowska@op.pl
Abstract:
According to WHO data the hepatitis C virus (HCV) has already infected 170 million people worldwide, and 750,000 of them in Poland what amounts some 1.4% of general country population. Currently used antiviral therapy with pegylated interferon alpha and ribavirin has only 50% effectiveness. Many new drugs and molecules, especially inhibiting viral replication, are studied in preclinical and clinical trials. However, still unknown HCV entry process can be a new, promising therapeutic target in chronic HCV infection.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Pharmacogenomics: Identification of New Drug Targets

